Tysabri
E24936
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
Aliases (1)
- natalizumab ×2
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
biologic therapy
→
immunosuppressive agent → medication → monoclonal antibody → |
| administeredIn |
infusion center
→
|
| approvedBy |
U.S. Food and Drug Administration
→
|
| approvedForIndication |
inducing and maintaining clinical response in adults with Crohn’s disease
→
relapsing forms of multiple sclerosis in adults → |
| associatedWithRiskFactor |
JC virus antibody positivity
→
|
| belongsToRegimenType |
disease-modifying therapy for multiple sclerosis
→
|
| blackBoxWarningFor |
progressive multifocal leukoencephalopathy
→
|
| canCause |
hepatotoxicity
→
hypersensitivity reactions → opportunistic infections → progressive multifocal leukoencephalopathy → |
| contraindicatedIn |
patients with a history of progressive multifocal leukoencephalopathy
→
patients with severely compromised immune systems → |
| developedBy |
Biogen
→
Elan Pharmaceuticals → |
| hasATCCode |
L04AA23
→
|
| hasDosingInterval |
every 4 weeks
→
|
| hasDrugClass |
integrin inhibitor
→
selective adhesion-molecule inhibitor → |
| hasFormulation |
concentrate for solution for infusion
→
|
| hasGenericName |
natalizumab
→
|
| hasHalfLife |
approximately 11 days
→
|
| hasMolecularType |
humanized monoclonal antibody
→
|
| improves |
disability outcomes in some patients with multiple sclerosis
→
|
| indicationRestriction |
generally reserved for Crohn’s disease patients who failed or are intolerant to conventional therapies
→
generally reserved for patients with inadequate response to other MS therapies → |
| isAdministeredBy |
healthcare professional
→
|
| isNotIndicatedFor |
pediatric multiple sclerosis in many regions
→
primary progressive multiple sclerosis → |
| isTradeNameOf |
natalizumab
→
|
| mechanismOfAction |
blocks adhesion of leukocytes to vascular endothelium
→
reduces migration of immune cells into the central nervous system → |
| pregnancyCategory |
may pose risk; use only if potential benefit justifies potential risk
→
|
| reduces |
formation of new MRI brain lesions in multiple sclerosis
→
relapse rate in relapsing multiple sclerosis → |
| requiresEnrollmentIn |
risk management program for PML
→
|
| requiresMonitoring |
liver function tests
→
signs and symptoms of progressive multifocal leukoencephalopathy → |
| routeOfAdministration |
intravenous infusion
→
|
| targets |
alpha-4 integrin
→
|
| usedFor |
Crohn’s disease
→
moderate to severe Crohn’s disease → relapsing forms of multiple sclerosis → relapsing-remitting multiple sclerosis → |
Referenced by (4)
| Subject (surface form when different) | Predicate |
|---|---|
|
Tysabri
("natalizumab")
→
|
hasGenericName |
|
Biogen
→
|
hasNotableDrug |
|
Biogen
→
|
hasProduct |
|
Tysabri
("natalizumab")
→
|
isTradeNameOf |